Last reviewed · How we verify
anlotinib or anlotinib plus anti-PD-1 antibody
anlotinib or anlotinib plus anti-PD-1 antibody is a Small molecule drug developed by Fudan University. It is currently FDA-approved.
At a glance
| Generic name | anlotinib or anlotinib plus anti-PD-1 antibody |
|---|---|
| Sponsor | Fudan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. (PHASE1, PHASE2)
- Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. (PHASE2)
- A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer (PHASE4)
- Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC (PHASE2)
- Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer (PHASE2)
- A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer (PHASE2)
- Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different Genotypes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anlotinib or anlotinib plus anti-PD-1 antibody CI brief — competitive landscape report
- anlotinib or anlotinib plus anti-PD-1 antibody updates RSS · CI watch RSS
- Fudan University portfolio CI
Frequently asked questions about anlotinib or anlotinib plus anti-PD-1 antibody
What is anlotinib or anlotinib plus anti-PD-1 antibody?
anlotinib or anlotinib plus anti-PD-1 antibody is a Small molecule drug developed by Fudan University.
Who makes anlotinib or anlotinib plus anti-PD-1 antibody?
anlotinib or anlotinib plus anti-PD-1 antibody is developed and marketed by Fudan University (see full Fudan University pipeline at /company/fudan-university).
What development phase is anlotinib or anlotinib plus anti-PD-1 antibody in?
anlotinib or anlotinib plus anti-PD-1 antibody is FDA-approved (marketed).